Literature DB >> 24148281

Establishment of an effective acute stroke telemedicine program for Australia: protocol for the Victorian Stroke Telemedicine project.

Dominique A Cadilhac1, Natasha Moloczij, Sonia Denisenko, Helen Dewey, Peter Disler, Bruce Winzar, Ian Mosley, Geoffrey A Donnan, Christopher Bladin.   

Abstract

RATIONALE: Urgent treatment of acute stroke in rural Australia is problematic partly because of limited access to medical specialists. Utilization of telemedicine could improve delivery of acute stroke treatments in rural communities. AIM: The study aims to demonstrate enhanced clinical decision making for use of thrombolysis within 4·5 h of ischemic stroke symptom onset in a rural setting using a telemedicine specialist support model.
DESIGN: A formative program evaluation research design was used. The Victorian Stroke Telemedicine program was developed and will be evaluated over five stages to ensure successful implementation. The phases include: (a) preimplementation phase to establish the Victorian Stroke Telemedicine program including the clinical pathway, data collection tools, and technology processes; (b) pilot clinical application phase to test the pathway in up to 10 patients; (c) modification phase to refine the program; (d) full clinical implementation phase where the program is maintained for one-year; and (e) a sustainability phase to assess project outcomes over five-years. Qualitative (clinician interviews) and quantitative data (patient, clinician, costs, and technology processes) are collected in each phase. STUDY OUTCOMES: The primary outcome is to achieve a minimum 10% absolute increase in eligible patients treated with thrombolysis. Secondary outcomes are utilization of the telestroke pathway and improvements in processes of stroke care (e.g., time to brain scan). We will report door to telemedicine consultation time, length of telemedicine consultation, clinical utility and acceptability from the perspective of clinicians, and 90-day patient outcomes.
SUMMARY: This research will provide evidence for an effective telestroke program for use in regional Australian hospitals.
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization.

Entities:  

Keywords:  ehealth; stroke; telemedicine; telestroke; thrombolysis

Mesh:

Year:  2013        PMID: 24148281     DOI: 10.1111/ijs.12137

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  4 in total

1.  Economic Evaluation Protocol and Statistical Analysis Plan for the Cost-Effectiveness of a Novel Australian Stroke Telemedicine Program; the Victorian Stroke Telemedicine (VST) program.

Authors:  Dominique A Cadilhac; Lauren Sheppard; Joosup Kim; Elise Tan; Lan Gao; Garveeta Sookram; Helen M Dewey; Christopher F Bladin; Marj Moodie
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

2.  Building cohesion in distributed telemedicine teams: findings from the Department of Veterans Affairs National Telestroke Program.

Authors:  Himalaya Patel; Teresa M Damush; Edward J Miech; Nicholas A Rattray; Holly A Martin; April Savoy; Laurie Plue; Jane Anderson; Sharyl Martini; Glenn D Graham; Linda S Williams
Journal:  BMC Health Serv Res       Date:  2021-02-06       Impact factor: 2.655

3.  Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.

Authors:  Angelos Sharobeam; Brett Jones; Dianne Walton-Sonda; Christian J Lueck
Journal:  J Neurol       Date:  2020-03-21       Impact factor: 4.849

4.  Integrating acute stroke telemedicine consultations into specialists' usual practice: a qualitative analysis comparing the experience of Australia and the United Kingdom.

Authors:  Kathleen L Bagot; Dominique A Cadilhac; Christopher F Bladin; Caroline L Watkins; Michelle Vu; Geoffrey A Donnan; Helen M Dewey; Hedley C A Emsley; D Paul Davies; Elaine Day; Gary A Ford; Christopher I Price; Carl R May; Alison S R McLoughlin; Josephine M E Gibson; Catherine E Lightbody
Journal:  BMC Health Serv Res       Date:  2017-11-21       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.